Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies the side effects of pomalidomide and how well it works
in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection.
Biological therapies, such as pomalidomide, may stimulate the immune system in different ways
and stop tumor cells from growing and it may also block the growth of new blood vessels
necessary for tumor growth.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
Montefiore Medical Center National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation University of Arkansas University of California, Los Angeles University of Stellenbosch Weill Medical College of Cornell University